tiprankstipranks
Trending News
More News >
Renalytix Plc (RNLXD)
:RNLXD

Renalytix (RNLXD) Price & Analysis

Compare
238 Followers

RNLXD Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

RNLXD FAQ

What was Renalytix Plc’s price range in the past 12 months?
Renalytix Plc lowest stock price was $3.13 and its highest was $8.10 in the past 12 months.
    What is Renalytix Plc’s market cap?
    Renalytix Plc’s market cap is $36.56M.
      When is Renalytix Plc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Renalytix Plc’s earnings last quarter?
      Currently, no data Available
      Is Renalytix Plc overvalued?
      According to Wall Street analysts Renalytix Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Renalytix Plc pay dividends?
        Renalytix Plc does not currently pay dividends.
        What is Renalytix Plc’s EPS estimate?
        Renalytix Plc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Renalytix Plc have?
        Renalytix Plc has 8,740,374 shares outstanding.
          What happened to Renalytix Plc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Renalytix Plc?
          Currently, no hedge funds are holding shares in RNLXD
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Renalytix Plc

            Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
            Popular Stocks